FIELD: medicine.
SUBSTANCE: patient receives autologous dendritic cells that are generated from peripheral blood cells using differentiation inducers loaded with antigens encoding viral proteins and induced to further maturation. Interleukin-2 is prescribed as adjuvant. As a antigen, a combination of fragments of recombinant viral Core (1-120 aq) and NS3 (1192-1457 aq) proteins is used, DC maturation is induced with azoximer bromide, dendritic cells are administered as 2 courses of subcutaneous vaccination, combining DC administration with subcutaneous intermittent injections of recombinant interleukin-2 as an adjuvant non-specific therapy for patients with chronic viral hepatitis C. Granulocyte-macrophage colony-stimulating factor and interferon-alpha are used as dendritic cells differentiation inducers.
EFFECT: method enables an increase of clinical effectiveness.
2 cl, 2 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION FOR TREATING HEPATITIS C AND METHOD OF TREATING HEPATITIS C | 2010 |
|
RU2447899C2 |
| METHOD FOR IMMUNOTHERAPY OF CHRONIC REFRACTORY HERPES VIRUS INFECTION | 2011 |
|
RU2485962C1 |
| METHOD OF GENERATION OF ANTIGEN-SPECIFIC CYTOTOXIC CELLS ACTIVE AGAINST HEPATITIS B INFECTED CELLS | 2008 |
|
RU2366707C1 |
| METHOD FOR GENERATION OF SPECIFIC IMMUNE RESPONSE ON HUMAN IMMUNODEFICIENCY VIRUS ANTIGENS | 2011 |
|
RU2465324C1 |
| METHOD FOR PREDICTION OF ANTIVIRAL THERAPY IN CHRONIC HEPATITIS C IN ADULTS AND CHILDREN | 2014 |
|
RU2589283C2 |
| METHOD FOR PREDICTION OF EFFICACY OF ANTIVIRAL THERAPY IN ADULT PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 1b | 2012 |
|
RU2522500C1 |
| IMMUNOBIOLOGICAL AGENT TO ENHANCE CELLULAR RESPONSE AGAINST HEPATITIS C VIRUS | 2023 |
|
RU2811136C1 |
| METHOD FOR PREDICTING ANTIVIRAL TREATMENT RESPONSE IN CHRONIC HEPATITIS C | 2013 |
|
RU2557534C2 |
| ANTI-HCV VACCINE | 2003 |
|
RU2323744C2 |
| METHOD OF GENERATING ANTIGEN-SPECIFIC CYTOTOXIC CELLS WITH ANTITUMOUR ACTIVITY IN BREAST CANCER | 2013 |
|
RU2521506C1 |
